Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2005

View Archived Issues

Patupilone shows promise in the treatment of multiple myeloma

Preclinical and clinical neuroprotective efficacy of statins in cerebral vascular disease

Preclinical data published on NBI-42902, a GnRH receptor antagonist

New data on the antitumor effects and toxicity of thalidomide monotherapy in HCC

Celecoxib shows promise in the prevention of intraabdominal adhesions

Novartis inlicenses rebamipide for dry eye

Phenserine fails to achieve significant efficacy in phase III Alzheimer's study

Viragen seeks expansion of approval for Multiferon in Sweden

Novavax receives NIH grant for SARS vaccine work

Cardiovascular drug candidate RUS-3108 enters phase I in Ireland

Takeda to acquire Syrxx

Phase I program of tgAAC-09 for HIV/AIDS expands to India

Portola begins phase Ib trial for oral anticoagulant

New Eloxatin formulation receives FDA approval

RiVax ricin vaccine enters clinical testing

Neurocrine prepares resubmission of indiplon NDAs

Ligand earns milestone for initiation of phase II for SB-497115

Fujisawa inlicenses ACR-16 from Carlsson Research

Evidence suggests that antihypertensive drugs improve severity of ischemic stroke

Improved outcome found with rosiglitazone in diabetic patients with cardiovascular disease

Pioglitazone reported to decrease carotid artery intimal thickness in obese subjects

Fendrix hepatitis B vaccine approved in Europe

BBB-permeable metal chelator shows promise for Alzheimer's treatment

Aston University team presents novel CCK1, CCK2 modulators

New 11beta-HSD1 inhibitors described in recent Merck patent

CRTH2 receptor ligands and their use for respiratory disorders reported by AstraZeneca

Gemin X discloses series of agents with anticancer and antiviral properties

Hydroxyfasudil prodrugs emerge from Schering R&D

Cardioprotective agents in early development at Dongbu Hannong

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...